Chronic pain affects more than 20% of the US population. More than a dozen new medical therapies are being developed to improve quality of life and reduce the risk of addition. This report summarizes the status of 17 new pain management medications in the pipeline: 16 in phase 3 trials and one newly approved.

The diagnosis and treatment of mantle cell lymphoma are covered in this podcast by Jonathon Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine. He also discusses how BTK inhibitors and CAR T-cell therapy are changing the treatment landscape and what he expects will be presented at upcoming conferences.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

JAK inhibitors have been the go-to treatment for people with myelofibrosis (MF). Despite successfully reducing MPN-related symptoms, currently approved JAK inhibitors are not known to significantly change the course of MF disease. Similar to essential thrombocythemia (ET) and polycythemia vera (PV), therapy in these conditions focus primarily on lowering the risk of cardiovascular and thromboembolic consequences; in individuals with reduced thrombosis risks, careful waiting is frequently employed. The creation of rationally tailored medicines, however, with the aim of not only managing illness problems but also potentially altering disease course, has resulted from a greater understanding of MPN biology.

Both as oral monotherapy and in combination with cetuximab, adagrasib exhibited antitumor activity in patients who had received prior treatment and had metastatic colorectal cancer with mutant KRAS G12C. In the group receiving combination therapy, the median response time was greater than 6 months. Reversible negative outcomes were frequent in both groups.

A mass measuring 4.8 cm by 5.0 cm by 3.9 cm was detected by transabdominal and transvaginal ultrasonography of the abdomen and pelvis. This mass was located along the posterior part of the right hepatic lobe. Following the clinic evaluation, there were two important questions to answer. Initially, was the adrenal tumor malignant or benign? Second, did the lesion secrete hormones?